Canada Life’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Canada Life's ARCT Position: Q1 2026 in Review
Canada Life increased its Arcturus Therapeutics (ARCT) stake by 6.5% in Q1 2026, buying an estimated $5.73K and bringing the position to 12,794 shares worth $99K. The position accounts for ﹤0.01% of the portfolio, ranked #1693.
Canada Life first reported a position in ARCT in Q2 2020 and has held it in 24 quarters since. The position peaked at $152K in Q1 2024. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Canada Life held 12,794 shares of Arcturus Therapeutics worth $99K as of Q1 2026.
- Canada Life bought 785 Arcturus Therapeutics shares in Q1 2026, an estimated $5.73K.
- Arcturus Therapeutics made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1693 holding.
- Canada Life first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 24 quarters since.
- Canada Life's Arcturus Therapeutics position peaked at $152K in Q1 2024.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.